Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

PURPOSE: The primary objectives of this phase I/II study were to evaluate the safety and immunogenicity of combination therapy consisting of concurrent trastuzumab and human epidermal growth factor receptor 2 (HER2)/neu-specific vaccination in patients with HER2/neu-overexpressing metastatic breast...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Disis, Mary L., Wallace, Danelle R., Gooley, Theodore A., Dang, Yushe, Slota, Meredith, Lu, Hailing, Coveler, Andrew L., Childs, Jennifer S., Higgins, Doreen M., Fintak, Patricia A., dela Rosa, Corazon, Tietje, Kathleen, Link, John, Waisman, James, Salazar, Lupe G.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2009
Materias:
Original Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2754913/
https://ncbi.nlm.nih.gov/pubmed/19720923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.6789
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares